Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
about
Energetics of the HIV gp120-CD4 binding reactionPathogenesis of human immunodeficiency virus infectionExpression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell lineKinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 bindingCT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virusAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivitySimple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.A baculovirus superinfection system: efficient vehicle for gene transfer into Drosophila S2 cells.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.A cis-acting repressive sequence that overlaps the Rev-responsive element of human immunodeficiency virus type 1 regulates nuclear retention of env mRNAs independently of known splice signals.The rev-responsive element negatively regulates human immunodeficiency virus type 1 env mRNA expression in primate cells.Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency virusesN-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposureAntibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptorTransmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7The auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence.Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding SitesDifferential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.Inhibition of HIV-1 entry by antibodies: potential viral and cellular targetsDifferences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells.Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis.The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45.HIV Entry and Its Inhibition by Bifunctional Antiviral ProteinsGenetic Strategies for HIV Treatment and Prevention
P2860
Q22254716-C56D56D9-DD85-4D8B-AE99-DF546C0719C7Q24634681-905E318F-B1A1-48AB-894D-293F75EF4432Q27478158-DF7E70F7-DA9A-44D0-8C8A-0815ACE4CFAEQ27734294-06DA06B2-C954-4667-9E1E-CA265AB19D5CQ28368118-EAC9428A-821D-45D1-BED6-DBE06AEB13C6Q28485983-759274C1-EED6-46ED-B554-8A366DC5F190Q33220705-EE0FEF04-F3DC-4498-9B62-C2C99850A7A8Q33782608-A4156014-2CA8-454B-AD3C-3C3F642B7D6DQ33813060-4536A1B6-632D-475A-A960-A1572BEBF292Q33813526-BF9D066E-E6D0-4247-8985-75640C08897BQ33853769-B48DB25A-8A56-499F-8D16-91CDC5FE47ACQ33936268-EFF88259-21C2-41E4-97CC-B95EF1456F0EQ35325810-11114C26-F26F-4739-81D1-75E469EC220DQ35694388-42C2E42A-607A-462F-9654-71D34843B9B0Q35867631-43DF54DC-1255-4570-8298-37C72469F723Q35868205-1DC37CC2-37A5-439E-9E30-394290814631Q35870903-FA444B1A-40E2-4E0E-920A-CBFEE0146520Q35886254-28B225BB-059D-4F34-8A3B-4E576403BF68Q35890867-F948F1EE-F79C-4DA1-80E8-71899A285B7BQ36000722-99901237-4F14-478F-9EEE-4900E37A19A2Q36055538-D5571EBE-B1C1-4C0C-9F6D-63ECCED5AE75Q36434294-E1E14B2B-3EC6-4455-A8B2-E246AAE70B1CQ36624656-A88A1F24-334F-45B7-94A0-DBF091AB7961Q36628256-9CE8D4AA-8A4F-4F24-B533-BD0F05D21215Q36629914-9ECF607D-B008-4392-BBEB-032785F8E96DQ36631937-A3EF36D1-454A-4714-83A9-7E0B522C64B1Q36632478-9CB85C46-32E0-4979-9CB4-27DC048F25F1Q36643604-250DA09E-4335-4AF7-B65A-F669BE536E8DQ36697574-69B7E109-05CA-49AC-B849-AB06705647C5Q36833874-D00C2B22-CB75-4F20-9DF0-813F5EF072AAQ38076139-A3D5C89A-09B3-4498-B335-BF89478BF10CQ39048904-2DDAD9B4-A2F9-47C9-9EE5-5BB02B62DFACQ39313957-DDFE5975-A035-4749-BAA4-F8D6767F4BADQ39868309-221472FD-7994-4C66-A62A-C6630B1FBACEQ39878965-C7B75FA1-7B9D-4C73-B0FD-C3A52AF02D11Q40397998-32DC69AE-2C71-4570-98F0-F0FD4CBE1A27Q40433970-2E9766E3-2EAB-4FE6-A709-62F4DD2B8435Q42264980-35B6446E-3325-47D9-8481-1AE7DF3932BAQ58555325-F2F55836-34A3-4247-BA85-28D8772EA4CAQ58604627-D433FB2D-33BD-45B9-86F6-5175A15F479A
P2860
Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@en
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@nl
type
label
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@en
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@nl
prefLabel
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@en
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@nl
P2093
P2860
P356
P1476
Envelope proteins from clinica ...... affinity for the CD4 receptor.
@en
P2093
Brighty DW
Ivey-Hoyle M
Rosenberg M
P2860
P304
P356
10.1073/PNAS.88.17.7802
P407
P577
1991-09-01T00:00:00Z